 Well, I think I'm going to have some mercy on all you people who are yawning and exhausted from two and a half days of this. John Mudget has also had to take off, so has anybody had a burning desire to have a discussion session? I don't think so. So it was a great meeting. I thought we really got a lot of work done on Sunday and the working groups, and then we demonstrated this huge amount of stuff that's been done to the PSC yesterday. I'm going to be asking them really for more of a scientific overview. I know they got really into process and really into details of reporting and all that kind of stuff, but we're looking for a feedback on this, on the basic high level scientific impact of the program. Something like what was discussed in the genes remaining, what have we accomplished in the big sense, and I think that will be forthcoming and it will be profound and important. So that's excellent. So and then today, talking about outreach and collaborations and impact on the community has been good. I know we're focused on like a renewal and we're appropriately focused on finishing the NOL resource, but what I hope you learned today was, and as we know, also from last year, there's a lot more to do with this platform than just finish the NOL resource. So we've done our segue into human disease gene, various in modeling and all that stuff and bringing the power of IMPC to bear on that. That will continue to expand and solve a lot of biological questions and patient issues. And I think the other dimension we have to start to investigate now is this work and move out and expand and use the platforms we've developed to answer other big or biological questions, right? So Dream, Blue Sky, Think Big, that's our mandate for this year. So thanks for coming and I guess we'll see you in Korea.